Exagen ( (XGN) ) has released its Q3 earnings. Here is a breakdown of the information Exagen presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Exagen Inc. is a prominent provider of autoimmune diagnostics, specializing in innovative testing solutions for chronic autoimmune conditions such as lupus and rheumatoid arthritis. The company operates in the healthcare sector, focusing on improving clinical outcomes through its comprehensive testing portfolio.
Exagen Inc. reported a robust performance for the third quarter of 2025, with a significant increase in revenue and improved financial metrics. The company achieved a record total revenue of $17.2 million, marking a 38% rise compared to the same period in 2024.
Key highlights from the earnings report include a 16% growth in AVISE CTD test volume and an increase in the average selling price to $441 per test. The company also ended the quarter with a strong cash position of $35.7 million. Strategic advancements included the commercial launch of seronegative RA markers and presentations at a major rheumatology conference.
Despite reporting a net loss of $7.1 million for the quarter, Exagen’s adjusted EBITDA showed improvement, reflecting better operational efficiency. The company remains optimistic about achieving positive adjusted EBITDA by the end of 2025, with expected full-year revenue between $65 million and $70 million.
Looking ahead, Exagen’s management is focused on maintaining its growth trajectory and enhancing its testing solutions to meet the evolving needs of the healthcare market. The company aims to continue its strategic initiatives to drive long-term value for stakeholders.